News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ICON-PLC (ICLR) Launches New Medical Imaging Solution for Early Phase Trials



10/17/2012 10:21:52 AM

Dublin, Ireland, 17 October, 2012 – ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the launch of a new medical imaging solution tailored to the unique requirements of early phase trials.

This new solution incorporates streamlined processes and procedures to maximise the information collected from image data and to ensure that this information is processed rapidly in line with the shorter timelines and requirements of early-phase research. Enhanced decision making is then enabled by MIRA™, ICON’s image management system, which standardises data from all imaging formats and allows for centralised analysis and interpretation of data. Driving this innovation is a team of scientific and regulatory experts with deep imaging and early-phase experience to help sponsors make critical decisions about their compounds faster.

“PET, volumetrics, advanced CT and MRI are increasingly being used in early phase research which has created a demand for more tailored imaging solutions for early phase trials,” commented Ted Gastineau, President, ICON Medical Imaging. “We have developed a unique and cost-effective solution that provides true insight to the data generated from imaging technologies and helps clients decide earlier about the future success of a drug.”

ICON Medical Imaging’s early phase group will be led by Dr. James Conklin, Senior Vice President, Medical and Scientific Affairs and Dr. Valerie Treyer, Director, Medical and Scientific Affairs, who together bring over 45 years of experience in the management of medical image data used in clinical trials. The group will work closely with ICON Development Solutions which provides a full range of early-phase services, including clinical pharmacology, bioanalytical, PK/PD modelling and simulation, and Clinical Pharmacodynamic Models for early indications of drug efficacy.

About ICON plc

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has over 9,200 employees, operating from 82 locations in 40 countries.

Media Contacts:

Yasamin Omoomian

Email: Yomoomian@webershandwick.com

Tel: +44 0207 067 0594


Read at BioSpace.com


comments powered by Disqus
ICON-PLC
ICON
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES